Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ebselen (Primary)
  • Indications Meniere's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms STOPMD-3
  • Sponsors Sound Pharmaceuticals

Most Recent Events

  • 20 Feb 2025 According to a Sound Pharmaceuticals media release, company will present data from this study at Pharmaceutical Interventions for Hearing Loss (PIHL) Satellite Symposium on Friday, Feb 21, at 1-5pm ET.
  • 10 Dec 2024 According to a Sound Pharmaceuticals media release ,company announce that the pivotal Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory compound (ebselen), for the treatment of Menieres Disease (STOPMD-3), achieved its co-primary endpoints for efficacy involving improvements in hearing loss and speech discrimination.
  • 10 Dec 2024 According to a Sound Pharmaceuticals media release, Primary endpoint (Change in low frequency hearing thresholds measured by pure tone audiometry) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top